By Gilang Cahya 
An international consortium of researchers, spearheaded by the University of California San Diego, has pinpointed a significant microbial culprit behind the disturbing surge in early-onset colorectal cancer: a potent bacterial toxin known as colibactin. This groundbreaking discovery, published on April 23 in the prestigious journal Nature, offers a critical piece of the puzzle in understanding why colorectal cancer, historically a disease of older age, is now increasingly diagnosed in younger adults.
The study’s findings illuminate a potential mechanism by which certain strains of Escherichia coli (E. coli), a common bacterium residing in the human gut, may initiate the complex cascade of events leading to cancer. Colibactin, a toxin produced by these specific E. coli strains, possesses the remarkable and dangerous ability to directly alter DNA. The research team’s meticulous analysis suggests that early-life exposure to colibactin can leave an indelible genetic mark on colon cells, a signature that significantly elevates the risk of developing colorectal cancer before the age of 50.
A Global Genetic Fingerprint: Uncovering Colibactin’s Role
The scale of this investigation is unprecedented, involving the comprehensive analysis of 981 colorectal cancer genomes. These genomes were sourced from patients across 11 countries, encompassing a diverse range of colorectal cancer incidence rates and varying degrees of early-onset disease. The researchers meticulously examined these genetic blueprints, searching for specific patterns of DNA mutations. Their findings were stark: the genetic signature left by colibactin was not uniformly distributed. Instead, it was found to be a striking 3.3 times more prevalent in early-onset colorectal cancer cases – specifically in individuals diagnosed under the age of 40 – when compared to those diagnosed at older ages, typically after 70. Furthermore, these colibactin-associated mutation patterns were disproportionately concentrated in countries experiencing a high incidence of early-onset colorectal cancer.
"These mutation patterns are essentially a historical record etched into the genome," explained Ludmil Alexandrov, the study’s senior author and a distinguished professor in the Shu Chien-Gene Lay Department of Bioengineering and the Department of Cellular and Molecular Medicine at UC San Diego. Professor Alexandrov, also a member of the UC San Diego Moores Cancer Center and Deputy Director of the Sanford Stem Cell Fitness and Space Medicine Center, emphasized the significance of this genetic evidence. "They strongly point towards early-life exposure to colibactin as a primary driving force behind the development of early-onset colorectal cancer."
While previous research, including earlier work from Professor Alexandrov’s lab, had hinted at the presence of colibactin-related mutations in a segment of all colorectal cancer cases (approximately 10 to 15 percent), those studies often focused on late-onset disease or did not differentiate between age groups. This latest Nature publication marks the first time researchers have demonstrated a substantial and statistically significant enrichment of these specific mutations in individuals who develop colorectal cancer at a younger age.
The Accelerating Epidemic of Early-Onset Colorectal Cancer
The implications of these findings are profound and deeply concerning. Colorectal cancer, once predominantly considered a disease affecting individuals in their later years, is now experiencing an alarming rise in younger populations. Data indicates that incidence rates in adults under 50 have roughly doubled every decade over the past 20 years in at least 27 countries. Projections based on current trends suggest that colorectal cancer could become the leading cause of cancer-related death among young adults by the year 2030.
The underlying reasons for this disturbing upward trend have remained largely elusive until now. Young adults diagnosed with colorectal cancer frequently lack a family history of the disease and often present with few of the traditionally recognized risk factors, such as obesity, physical inactivity, or hypertension. This diagnostic paradox has fueled intense speculation regarding the potential role of hitherto unrecognized environmental exposures or microbial influences. The current study directly addresses this gap in knowledge by providing compelling evidence for a microbial contributor.
"When we embarked on this project, our initial intention was not to solely focus on early-onset colorectal cancer," revealed Marcos Díaz-Gay, a co-first author of the study and a former postdoctoral researcher in Professor Alexandrov’s lab. "Our original objective was to investigate global patterns of colorectal cancer to understand the disparities in incidence rates between different countries. However, as we delved deeper into the extensive dataset, one of the most striking and unexpected revelations was the sheer frequency with which colibactin-related mutations appeared in the early-onset cases."
The Silent Initiation: Colibactin’s Early Impact on DNA
The research team’s molecular clock analysis has provided critical insights into the timeline of colibactin’s damaging effects. By precisely dating each identified mutational signature, they have demonstrated that colibactin-associated mutations are not a late-stage phenomenon but rather arise early in the tumor development process. This finding aligns with prior studies suggesting that such mutations can occur within the first decade of life. Furthermore, the study reveals that colibactin-related mutations account for approximately 15 percent of what are known as "APC driver mutations" – fundamental genetic alterations that directly initiate and promote cancer development – within colorectal cancer genomes.
Professor Alexandrov elaborated on this crucial point: "If an individual acquires one of these critical driver mutations by the age of 10, they could essentially be decades ahead of the typical timeline for developing colorectal cancer, potentially leading to a diagnosis at age 40 instead of 60." This suggests a scenario where colibactin-producing bacteria may silently colonize children’s intestines, initiating subtle but significant molecular changes in their DNA that lay the groundwork for colorectal cancer development long before any physical symptoms manifest.
While the evidence presented in the Nature study offers robust support for this hypothesis, Professor Alexandrov prudently cautioned that further research is essential to definitively establish causality. Nevertheless, the identification of a specific bacterial toxin with a demonstrable genetic fingerprint strongly linked to early-onset disease represents a significant leap forward in understanding this complex medical mystery.
Building on Decades of Research: The Power of Mutational Signatures
This pivotal study is the latest milestone in the ongoing work of the Cancer Grand Challenges team, Mutographs, funded by Cancer Research UK. Professor Alexandrov, Dr. Díaz-Gay, and their colleagues have dedicated years to advancing research in the field of mutational signatures. Their expertise lies in deciphering the unique genetic imprints left by various environmental exposures, including ultraviolet radiation and bacterial toxins, as well as lifestyle factors such as smoking and alcohol consumption. Each of these factors, through their interaction with DNA, leaves behind a distinct pattern of mutations – a molecular fingerprint that can serve as a crucial clue in pinpointing the origins of specific cancers.
This collaborative effort, a long-term partnership between UC San Diego, the International Agency for Research on Cancer in France, and the Wellcome Sanger Institute in the UK, has already yielded significant insights into the mutational processes underlying other major cancers, including esophageal, kidney, and head and neck cancers worldwide. The recent findings on colorectal cancer further expand this global understanding of cancer etiology through the systematic application of mutational signature analysis. By meticulously cataloging these diverse mutational patterns across thousands of cancer genomes, the researchers aim to uncover novel causes of cancer that may have previously escaped detection.
"Not every environmental factor or behavior we investigate leaves a discernible mark on our genome," Professor Alexandrov noted. "However, we have found that colibactin is one such factor that does. In this particular instance, its genetic imprint appears to be strongly associated with the development of colorectal cancers in young adults."
The Road Ahead: Unanswered Questions and Future Directions
The discovery of colibactin’s potential role in early-onset colorectal cancer opens a Pandora’s Box of new questions and necessitates urgent further investigation. Key among these are:
- Exposure Pathways: How are children being exposed to colibactin-producing E. coli strains? Are there specific environmental factors, dietary habits, or lifestyle behaviors that promote the production or colonization of these bacteria?
- Preventative Strategies: What measures can be implemented to prevent or mitigate colibactin exposure in early life?
- Early Detection: Can individuals be tested to determine if they carry these colibactin-induced mutations?
- Therapeutic Interventions: Could interventions, such as the use of probiotics, be a safe and effective way to eliminate harmful bacterial strains or reduce the risk associated with colibactin exposure?
The research team is actively pursuing several avenues of inquiry to address these critical questions. They are continuing to examine the correlation between colibactin exposure and the risk of early-onset colorectal cancer, while also exploring the potential of probiotics for eliminating harmful bacterial strains. A significant focus is also being placed on the development of early detection tests that can analyze stool samples for the presence of colibactin-related mutations, potentially enabling intervention before the disease progresses.
Broader Implications: A Paradigm Shift in Cancer Understanding
Beyond the specific focus on colorectal cancer, the findings carry broader implications for how we understand the origins of cancer in general. The study underscores the possibility that many cancers may originate from environmental or microbial exposures encountered much earlier in life, potentially decades before diagnosis.
"This research has the potential to fundamentally reshape our understanding of cancer," Professor Alexandrov stated. "It suggests that cancer development may not solely be a consequence of events occurring in adulthood. Instead, it could be significantly influenced by experiences in early life, perhaps even within the first few years of existence. Sustained investment in this type of research is absolutely critical for the global effort to prevent and treat cancer effectively, before it becomes a life-threatening disease."
The Mutographs team is also continuing its global search for other cancer-linked mutational signatures. Their recent Nature study also identified increased prevalence of specific mutational signatures in colorectal cancers from certain countries, including Argentina, Brazil, Colombia, Russia, and Thailand. This suggests that localized environmental exposures may play a significant role in cancer risk in different regions.
"It is plausible that distinct countries may harbor unique, as-yet-undiscovered causes of cancer," observed Dr. Díaz-Gay, who is now launching a new phase of this research at the Spanish National Cancer Research Center (CNIO) in Madrid. "This realization opens up the exciting potential for developing targeted, region-specific prevention strategies that are tailored to local risk factors and exposures."
The comprehensive approach of analyzing mutational signatures across diverse populations and cancer types is a powerful tool in the ongoing fight against cancer, offering hope for earlier detection, more effective prevention, and ultimately, improved outcomes for patients worldwide.
